4530 Stock Overview
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JPÂ¥3,649.00 |
52 Week High | JPÂ¥4,065.00 |
52 Week Low | JPÂ¥3,230.00 |
Beta | 0.56 |
1 Month Change | -3.08% |
3 Month Change | -3.34% |
1 Year Change | 8.93% |
3 Year Change | -33.78% |
5 Year Change | -60.47% |
Change since IPO | 727.44% |
Recent News & Updates
Recent updates
Shareholder Returns
4530 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 0.1% | 2.7% | 2.6% |
1Y | 8.9% | 18.8% | 13.6% |
Return vs Industry: 4530 underperformed the JP Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: 4530 underperformed the JP Market which returned 13.6% over the past year.
Price Volatility
4530 volatility | |
---|---|
4530 Average Weekly Movement | 2.7% |
Pharmaceuticals Industry Average Movement | 3.4% |
Market Average Movement | 3.7% |
10% most volatile stocks in JP Market | 7.8% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4530 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4530's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1847 | 2,769 | Kazuhide Nakatomi | https://www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
4530 fundamental statistics | |
---|---|
Market Cap | JPÂ¥282.21b |
Earnings (TTM) | JPÂ¥11.74b |
Revenue (TTM) | JPÂ¥128.33b |
24.2x
P/E Ratio2.2x
P/S RatioIs 4530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4530 income statement (TTM) | |
---|---|
Revenue | JPÂ¥128.33b |
Cost of Revenue | JPÂ¥55.63b |
Gross Profit | JPÂ¥72.70b |
Other Expenses | JPÂ¥60.96b |
Earnings | JPÂ¥11.74b |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
Jul 13, 2023
Earnings per share (EPS) | 151.03 |
Gross Margin | 56.65% |
Net Profit Margin | 9.15% |
Debt/Equity Ratio | 0.5% |
How did 4530 perform over the long term?
See historical performance and comparison